Zim Laboratories growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue−1.2%−2.1%
EBITDA−31.4%−16.7%
Net Income−52.0%−37.9%
EPS (adj.)−52.0%−37.9%
Total Assets+14.3%+16.4%
Total Equity+17.4%+13.9%
Free Cash Flow+1,344.9%+82.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ZIMLAB₹141.26

Zim Laboratories Limited

· Pharma & Health
₹ CrorePeersANUHPHRVALIANTLABAHCLALBERTDAVDWANBURYHALEOSLABSBAJAJHCARETHEMISMEDMcap ₹756 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue-1.2-2.1
EBITDA-31.4-16.7
Net Income-52.0-37.9
EPS (adj.)-52.0-37.9
Total Assets+14.3+16.4
Total Equity+17.4+13.9
Free Cash Flow+1344.9+82.1
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.